Scorpius Holdings Secures $248K in High-Cost, Restrictive Short-Term Debt Amidst Severe Financial Distress
SCPX filed a Financing and Capital Events on light trading volume (0.3× avg).
Summary
Scorpius Holdings, a micro-cap company, secured $248,443 in highly expensive and restrictive short-term debt from an institutional investor, highlighting its severe financial distress and challenging future capital raises.
Key Events · Financing and Capital Events · SCPX
-
Secured $248K in New Debt
Scorpius Holdings issued three non-convertible promissory notes totaling $248,443.82 to an institutional investor between February 12 and March 11, 2026.
-
High Cost and Short-Term
The notes carry a 5.0% interest rate and require a 15% premium on the principal amount upon repayment, with maturities ranging from August to September 2026.
-
Restrictive Redemption Clause
The noteholder has the right to demand full redemption of the outstanding balance, including the 15% premium, from the gross proceeds of any future company financing.
-
Addresses Immediate Liquidity Needs
This debt provides a temporary cash infusion for a company that reported less than $0.1 million in cash as of February 17, 2026, and a going concern warning.
Analysis · SCPX · Life Sciences
This 8-K reveals Scorpius Holdings has obtained critical, albeit highly unfavorable, short-term financing totaling $248,443 through three non-convertible promissory notes. The terms, including a 5.0% interest rate, a 15% premium on principal repayment, and maturities within 6-7 months, reflect the company's severe financial distress, as previously indicated by its going concern warning and critically low cash reserves. Critically, the notes include a clause allowing the holder to demand full redemption from the proceeds of any future financing, which could severely impede the company's ability to raise capital for operations or growth. This financing provides a temporary lifeline but at a significant cost and with substantial future restrictions, underscoring the precariousness of the company's financial position.
At the time of this filing, SCPX was trading at $0.01 on OTC in the Life Sciences sector, with a market capitalization of approximately $770.4K. The 52-week trading range was $0.00 to $0.35. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.